Amgen (AMGN): FY26 Q3 earnings call, Nov 3, 2026
On its Nov 3, 2026 earnings call (FY26 Q3), Amgen said 6 of the 14 words Kalshi listed; Parrot’s count agreed with all 14 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
14 words · 6 settled yes · our count agreed on 14 of 14- Kalshi: company speakers + operator
Kalshi
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Dazodalibep | Yes | 9 | 9 | ✓ | 70%transcripts from the transcript model | – |
| Eosinophilic | Yes | 6 | 6 | ✓ | 65%transcripts from the transcript model | – |
| ESMO | Yes | 5 | 7 | ✓ | 31%transcripts from the transcript model | – |
| Imfinzi / Durvalumab | Yes | 5 | 5 | ✓ | 20%transcripts from the transcript model | – |
| GLP-1 / GLP | Yes | 4 | 5 | ✓ | 78%transcripts from the transcript model | – |
| Medicare | Yes | 1 | 2 | ✓ | 39%transcripts from the transcript model | – |
| Oral 3+ times | No | 1 | 1 | ✓ | 55%transcripts from the transcript model | – |
| Artificial Intelligence 3+ times | No | 1 | 1 | ✓ | 28%transcripts from the transcript model | – |
| Tavneos | No | 0 | 0 | ✓ | 68%transcripts from the transcript model | – |
| Acquisition | No | 0 | 0 | ✓ | 53%transcripts from the transcript model | – |
| Prolia 2+ times | No | 0 | 0 | ✓ | 35%transcripts from the transcript model | – |
| Litigation | No | 0 | 0 | ✓ | 31%transcripts from the transcript model | – |
| Patent 2+ times | No | 0 | 0 | ✓ | 29%transcripts from the transcript model | – |
| Buyback / Buy Back | No | 0 | 0 | ✓ | 16%transcripts from the transcript model | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Nov 3, 2026 23:56 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
7 matches for “ESMO”; 5 quoted, at least 25 words apart.
…first-line maintenance study of IMDELLTRA with anti-PD-L1 therapy was also presented at ESMO, remarkably featuring a median overall survival of 37 months. These results are…
…of that, how quickly you believe the product can ramp following the ESMO data? As part of that answer, just can you also talk about…
…out there this week and last week post-presentation of the data at ESMO, and I'm not alone in my enthusiasm for these data. Our practicing…
…for taking my question. I just wanted to echo the sentiment from ESMO on the groundbreaking data. Murdo, maybe just to expand on Chris's question…
…as the data from the DeLLphi study presented in the presidential at ESMO and published in The New England Journal recently, that as these data…
Where the listed words were said
…cornerstone therapy, TEZSPIRE in eosinophilic esophagitis, an area with significant unmet need, and dazodalibep in Sjögren's disease, where no approved disease-modifying therapies currently exist.
…in the need for surgery. More recently, positive phase III results in eosinophilic esophagitis, or EoE, demonstrated meaningful improvements in key measures of disease activity…
…as well as a fully outpatient cohort, which we have presented at ESMO in phase I-B, which demonstrated for xaluritamig, our STEAP1 CD3 bispecific that…
…phase III results from the DeLLphi-305 study evaluating IMDELLTRA in combination with IMFINZI in first-line maintenance treatment. I was at the European Society for Medical…
…start and stay on MariTide, and how others can switch from other GLP-1-based medicines and stay on MariTide. Our goal is to make long-term treatment…
…we're interested in seeing what other government access programs evolve to over time. I think it's good that we've got Medicare access in this category.
Agents: this page as TSV at /api/v1/appearances/amgen:2026-11-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-11-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP